Acrongenomics Inc. Further Develops Its Nano-JETA Platform.ATHENS, Greece -- Acrongenomics Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :AGNM) a Research and Development company focused in the field of nanobiotechnology is exploring future prospects by evaluating the technology behind existing implementations of PCR PCR polymerase chain reaction. PCR abbr. polymerase chain reaction Polymerase chain reaction (PCR) , ELISA ELISA (e-li´sah) Enzyme-Linked Immuno-Sorbent Assay; any enzyme immunoassay using an enzyme-labeled immunoreactant and an immunosorbent. ELISA n. and Real Time PCR. According to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. our market research, current applications reveal certain limitations, including problems with efficiencies and cost effectiveness. Acrongenomics Inc. endeavors to overcome these limitations by introducing nanotechnology into molecular biology molecular biology, scientific study of the molecular basis of life processes, including cellular respiration, excretion, and reproduction. The term molecular biology was coined in 1938 by Warren Weaver, then director of the natural sciences program at the Rockefeller . Nanotechnology is beginning to generate substantial new insights into how biological systems function and is believed to hold potential advances in both the pharmaceuticals and health care industries. Acrongenomics Inc. believes that its first application, the Neo-EpCAM(TM) Cancer detection kit provides enhanced performance as a result of its ongoing Nano-JETA(TM) platform, which combines nanotechnology with molecular biology and applies in PCR, enzyme reactions - including universal ELISA Detection Systems - and Real Time PCR. In total, 97 different tissue samples from patients suffering from laryngeal cancer laryngeal cancer Malignant tumour of the larynx. The larynx is affected by both benign and malignant tumours. Squamous-cell carcinoma, the most common laryngeal malignancy, is associated with smoking and alcohol consumption; it is more common in men. , and 82 different tissue samples from patients suffering from breast cancer were used for standardization, evaluation, validation and characterization of our Neo-EpCAM(TM) cancer detection kit. A characterization and evaluation report for Neo-EpCAM(TM) has been completed in universal PCR and ELISA. By advancing our know-how in nanotechnology, we managed to apply our Nano-JETA(TM) platform on the detection of more markers and viral targets such as Neo-EpCAM(TM), HER1, HER2, HER3, and HER4, with the incorporation of the appropriate primers. A characterization and evaluation report has been completed in PCR and ELISA. --750 tests were performed in colon and breast cancer samples --750 tests were performed in colon and laryngeal cancer samples --250 tests were also performed in breast and laryngeal cancer samples In essence, Nano-JETA(TM) Platform shows a potential in eliminating all known limitations of current technologies. These developments led to the reshaping of both Conventional PCR and ELISA, to Nano-JETA(TM) PCR, and Universal Nano-JETA(TM) ELISA respectively without compromising sensitivity, specificity and reliability. Realizing the potential applications of our Nano-JETA(TM) Platform is of crucial importance in understanding its diversity. There is a large number of possible permutations waiting to be explored, and therefore Acrongenomics has evolved Nano-JETA(TM) Platform in Real-Time PCR application for "markers" such as EpCAM, HER1, HER2, and vEGF by conducting clinical validation trials in 400 samples of breast, colon, lung and ovarian cancer ovarian cancer Malignant tumour of the ovaries. Risk factors include early age of first menstruation (before age 12), late onset of menopause (after age 52), absence of pregnancy, presence of specific genetic mutations, use of fertility drugs, and personal history of breast anticipating completion by the end of March 2005. Preliminary indications reveal precision, accuracy, specificity and reproducibility. By evolving our proprietary technology, we have currently achieved a typical Real-Time PCR in 47 seconds without compromising sensitivity, specificity and reliability. Nano-JETA(TM) platform as an application for Real Time PCR uses common Real Time PCR equipment revealing qualitative results even from the first cycle reaching maximum performance at the eighth cycle. In addition, with such achievements and in order to strengthen our position, we have decided to conduct independent validation studies in U.S. Molecular diagnostic testing Diagnostic testing Testing performed to determine if someone is affected with a particular disease. Mentioned in: Von Willebrand Disease is the fastest-growing segment of the in vitro diagnostics In vitro diagnostic (IVD) tests are medical tests conducted in a test tube, or more generally in a controlled environment outside a living organism. In vitro means in glass in Latin. industry. The last four years, clinical market for molecular diagnostic products has increased from $1 billion in 2000 to 2,8 billion in 2004 and sales are expected to exceed $5 billion by 2008 (Biotechnology Associates). So profitable is the molecular diagnostics market that pharmaceutical and biotechnology companies Top 100 Biotechnology Companies The following is a list of the top 100 biotechnology companies ranked by revenue. The first nine companies qualify for the list of the top 50 pharmaceutical companies. are highly focused in developing tests that can be used to guide prescribing, and individualize in·di·vid·u·al·ize tr.v. in·di·vid·u·al·ized, in·di·vid·u·al·iz·ing, in·di·vid·u·al·iz·es 1. To give individuality to. 2. To consider or treat individually; particularize. 3. patient treatment. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion